AMD Therapeutics Market Growth Driven by Aging Population and Advances in Eye Care Treatments

The AMD therapeutics market is growing due to rising aging populations and advances in eye care treatments. Anti VEGF therapies lead current care while innovations like gene therapy and sustained delivery systems expand options despite cost and access challenges globally.

News Mar 24, 2026 0 2 Add to Favourites

AMD Therapeutics Market Growth Driven by Aging Population and Advances in Eye Care Treatments

According to a new report from Intel Market Research, the global Age-Related Macular Degeneration (AMD) Therapeutics market was valued at USD 7.81 billion in 2024 and is projected to reach USD 11.84 billion by 2034, growing at a CAGR of 6.3% during the forecast period (2025-2034). This growth trajectory reflects the increasing prevalence of retinal disorders among aging populations and technological advancements in treatment modalities.

Understanding Age-Related Macular Degeneration (AMD)

AMD represents a leading cause of vision loss among older adults, characterized by progressive deterioration of the macula - the central portion of the retina responsible for sharp visual acuity. The disease manifests in two primary forms:

Dry AMD (non-neovascular): Accounting for 85-90% of cases, characterized by drusen deposits and gradual thinning of macular tissues
Wet AMD (neovascular): More severe form involving abnormal blood vessel growth beneath the retina, responsible for 90% of severe vision loss cases

Current treatment paradigms focus on anti-VEGF therapies for wet AMD, while dry AMD management remains largely supportive with nutritional supplementation. Emerging approaches including gene therapies and sustained-release drug delivery systems are reshaping the therapeutic landscape.

???? Download FREE Sample Report: Age-Related Macular Degeneration (AMD) Therapeutics Market - View in Detailed Research Report

Market Growth Drivers

1. Aging Demographics and Rising Disease Burden
The global population aged 60+ is projected to reach 2.1 billion by 2050, with over 200 million expected to develop AMD. This demographic shift creates unprecedented demand for effective retinal therapies, particularly in developed markets with advanced healthcare infrastructure. The American Academy of Ophthalmology reports that AMD prevalence nearly doubles with each decade after age 50, reaching 30% among individuals over 75.

2. Breakthroughs in Anti-VEGF Therapies
The introduction of vascular endothelial growth factor inhibitors revolutionized AMD treatment, with drugs like ranibizumab (Lucentis) and aflibercept (Eylea) becoming standard of care. These biologics demonstrate remarkable efficacy in preserving and even improving vision, with clinical trials showing over 90% of patients maintaining visual acuity after 2 years of treatment. The market has witnessed 12% CAGR growth specifically for anti-VEGF therapies, driven by innovations in drug formulations and delivery mechanisms.

➤ Industry data indicates anti-VEGF injections account for 65% of AMD therapeutics revenue, with extended-duration formulations improving patient compliance

3. Expanding Pipeline for Dry AMD Treatments
After years of limited options, the therapeutic pipeline for geographic atrophy (advanced dry AMD) shows promising developments:

Complement inhibitors targeting inflammatory pathways
Neuroprotective agents preserving retinal cells
Stem cell therapies for retinal regeneration

These emerging modalities address a significant unmet need, as currently approved dry AMD treatments primarily involve dietary supplements lacking disease-modifying effects.

Market Challenges

High Treatment Costs - Annual expenses exceeding $10,000 per patient create access barriers, particularly in developing regions without robust reimbursement systems
Treatment Burden - Frequent intravitreal injections (typically monthly) pose adherence challenges for elderly patients
Regulatory Hurdles - Rigorous FDA/EMA approval processes requiring extensive clinical evidence can delay market entry by 7-10 years
Diagnostic Limitations - Many cases remain undiagnosed until advanced stages, particularly in resource-limited settings

Emerging Opportunities

The AMD therapeutics market presents several promising avenues for growth and innovation:

1. Gene Therapy Advancements
Early-stage gene therapies show potential to transform AMD treatment with single-administration solutions offering durable effects. Initial clinical data suggests these therapies could capture 30% market share within three years of approval, significantly reducing treatment burden compared to current anti-VEGF regimens.

2. Sustained-Release Drug Delivery Systems
Developing technologies include:

Implantable devices providing continuous drug release
Port delivery systems extending treatment intervals
Biodegradable inserts gradually releasing therapeutics

These innovations aim to maintain therapeutic efficacy while minimizing injection frequency and associated complications.

3. Biosimilars Market Expansion
With key anti-VEGF biologics facing patent expirations, biosimilar competition is emerging to improve affordability. While currently representing less than 15% of AMD prescriptions due to physician hesitancy, biosimilars are expected to gain traction in price-sensitive markets through 2030.

???? Download Sample PDF: https://www.intelmarketresearch.com/download-free-sample/33444/age-related-macular-degeneration-therapeutics-market

Regional Market Analysis

North America: Dominates the global market with 48% share, driven by high treatment adoption, advanced healthcare infrastructure, and favorable reimbursement policies (Medicare covers AMD therapies)
Europe: Second largest market with centralized healthcare systems; Germany and France lead in adoption of premium therapies
Asia-Pacific: Fastest growing region (projected 8.1% CAGR) due to expanding elderly populations and improving diagnostic capabilities in Japan, China, and Australia
Latin America: Moderate growth, with Brazil and Mexico establishing specialized retinal care centers
Middle East & Africa: Emerging market concentrated in Gulf countries, with growing awareness and healthcare investments

Market Segmentation

By Type

Wet AMD
Dry AMD

By Drug Class

Anti-VEGF Agents (Lucentis, Eylea, Avastin)
Complement Inhibitors
Others

By Treatment Approach

Pharmacological
Gene Therapy
Stem Cell Therapy

By End User

Hospitals
Specialty Clinics
Research Institutes

By Region

North America
Europe
Asia-Pacific
Latin America
Middle East & Africa

???? Get Full Report Here: Age-Related Macular Degeneration (AMD) Therapeutics Market - View Detailed Research Report

Competitive Landscape

The AMD therapeutics market features a mix of established pharmaceutical giants and innovative biotech firms:

Market Leaders

Roche/Genentech (Lucentis)
Regeneron Pharmaceuticals (Eylea)
Novartis

Emerging Innovators

Apellis Pharmaceuticals (pegcetacoplan for geographic atrophy)
Iveric Bio (Zimura complement inhibitor)
Kodiak Sciences (KSI-301 extended durability anti-VEGF)

The competitive environment is intensifying as companies race to develop next-generation therapies with improved efficacy, durability, and patient convenience.

Report Coverage

Comprehensive market sizing and growth projections through 2034
Detailed analysis of therapeutic segments and pipeline products
Competitive intelligence on 15+ key market players
SWOT analysis and market entry strategies
Regulatory landscape and reimbursement analysis
Emerging technology assessment

???? Get Full Report: https://www.intelmarketresearch.com/age-related-macular-degeneration-therapeutics-market-33444

???? Download Sample Report: https://www.intelmarketresearch.com/download-free-sample/33444/age-related-macular-degeneration-therapeutics-market

About Intel Market Research

Intel Market Research is a leading provider of strategic intelligence, offering actionable insights in biotechnology, pharmaceuticals, and healthcare infrastructure. Our research capabilities include: